This article first appeared on GuruFocus .
-
Q4 FY26 Revenue:$15,652 million.
-
Full Year FY26 Revenue:$67,137 million.
-
EBITDA Margin:25% for the full year.
-
Gross Margin:58% for the full year and the quarter.
-
Pharma Business Growth:40% growth for the full year.
-
Net Cash:Rupees 34 billion.
-
Trade Working Capital:139 days of sales.
-
New Molecules Commercialized:Five in EQM exports.
-
New Product Launches:Four in domestic agri brands (three herbicides, one insecticide).
-
Effective Tax Rate (ETR):22% for FY26, expected 23%-24% for FY27.
-
Warning! GuruFocus has detected 2 Warning Sign with BOM:523642.
-
Is BOM:523642 fairly valued? Test your thesis with our free DCF calculator.
Release Date: May 20, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
PI Industries Ltd ( BOM:523642 ) reported a consolidated revenue of $67,137 million with healthy EBITDA margins of 25%, showcasing resilience in a challenging market.
-
The company's pharma business delivered a 40% growth for the full year, indicating strong customer engagement and investment in capabilities.
-
PI Industries Ltd ( BOM:523642 ) has maintained its position in the S&P Global Yearbook, with an improved percentile of 98, highlighting its commitment to sustainability.
-
The company has commercialized five new molecules in EQM exports and launched four new products in domestic agri brands, contributing to a focused de-risking strategy.
-
PI Industries Ltd ( BOM:523642 ) has successfully implemented SAP S/4HANA, marking a key milestone in its digital transformation journey, enhancing operational efficiency and governance.
Negative Points
-
The global crop protection market continues to face a multi-year down cycle, with recovery remaining uneven due to global events and conflicts.
-
Domestic agrochemical demand has been impacted by channel inventory, pricing pressure, and lower crop acreages, affecting key crops.
-
The company's asset turns have decreased from 2.5x to 1.5x, with a significant CapEx not yet translating into expected revenue growth.
-
There is a noted decline in EQM exports due to lower volumes, reflecting broader global industry contraction and customer delivery schedules.
-
The company faces challenges in the pharma sector due to external environment investments and reduced biotech startup activities, impacting growth momentum.
Q & A Highlights
Q: Could you explain the significant CapEx over the last three years and its impact on revenue? A: The CapEx has been directed towards multi-year ramp-ups in capacities and technology investments. These are long-term projects, and while the gestation period has extended, we expect them to contribute to revenue in the coming years. (Mayank Singhal, Executive Vice Chairman and Managing Director)
Q: What is the outlook for growth excluding your largest product in the agro CSM business? A: New molecules contribute around 18-20% of our portfolio and are growing faster. Despite challenges, we expect growth from these new products as the market conditions improve. (Sanjay Agarwal, Group CFO)
Q: Can you provide insights into the margins and expectations for FY27? A: We aim to maintain gross margins at current levels, though volatility may affect quarterly results. EBITDA margins are subject to input costs and other factors, but we focus on managing them effectively. (Mayank Singhal, Executive Vice Chairman and Managing Director)
Q: What is the potential of the new biological nematode product launched in the US? A: This unique product, which allows foliar application, is expected to see significant growth, especially in markets like the US and Brazil. We anticipate tripling sales in Brazil this year. (Mayank Singhal, Executive Vice Chairman and Managing Director)
Q: How do you see the electronic chemicals segment evolving in the next few years? A: We are investing significantly in this area, with plans to reach $100 million in revenue over the next 4-5 years. The focus is on niche applications with high growth potential. (Mayank Singhal, Executive Vice Chairman and Managing Director)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
